Response to: "Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers

被引:1
作者
Emery, P. [1 ,2 ]
Bingham, C. O., III [3 ]
Burmester, G. R. [4 ]
Bykerk, V. P. [5 ]
Furst, D. E. [6 ]
Mariette, X. [7 ]
van der Heijde, D. [8 ]
van Vollenhoven, R. [9 ]
Arendt, C. [10 ]
Mountian, I. [10 ]
Purcaru, O. [10 ]
Tatla, D. [11 ]
VanLunen, B. [11 ]
Weinblatt, M. E. [12 ]
机构
[1] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[2] Leeds Teaching Hosp NHS Trust, NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England
[3] Johns Hopkins Univ, Baltimore, MD USA
[4] Charite, Berlin, Germany
[5] Hosp Special Surg, Weill Cornell Med Coll, Div Rheumatol, 535 E 70th St, New York, NY 10021 USA
[6] Univ Calif Los Angeles, David Geffen Sch Med, Div Rheumatol, Los Angeles, CA 90095 USA
[7] Univ Paris 11, Hop Univ Paris Sud, AP HP, INSERM,U1184, Le Kremlin Bicetre, France
[8] Leiden Univ, Med Ctr, Leiden, Netherlands
[9] Karolinska Inst, Unit Clin Therapy Res, Inflammatory Dis, Stockholm, Sweden
[10] UCB Pharma, Brussels, Belgium
[11] UCB Pharma, Raleigh, NC USA
[12] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA
关键词
Early Rheumatoid Arthritis; DMARDs (biologic); Methotrexate; RHEUMATOID-ARTHRITIS; RECOMMENDATIONS;
D O I
10.1136/annrheumdis-2016-210083
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
引用
收藏
页码:E69 / E69
页数:1
相关论文
共 9 条
[1]
Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease! [J].
Boers, Maarten .
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (10) :E68-E68
[2]
Identifying flares in rheumatoid arthritis: reliability and construct validation of the OMERACT RA Flare Core Domain Set [J].
Bykerk, Vivian P. ;
Bingham, Clifton O. ;
Choy, Ernest H. ;
Lin, Daming ;
Alten, Rieke ;
Christensen, Robin ;
Furst, Daniel E. ;
Hewlett, Sarah ;
Leong, Amye ;
March, Lyn ;
Woodworth, Thasia ;
Boire, Gilles ;
Haraoui, Boulos ;
Hitchon, Carol ;
Jamal, Shahin ;
Keystone, Edward C. ;
Pope, Janet ;
Tin, Diane ;
Thorne, J. Carter ;
Bartlett, Susan J. .
RMD OPEN, 2016, 2 (01)
[3]
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study [J].
Emery, P. ;
Bingham, C. O., III ;
Burmester, G. R. ;
Bykerk, V. P. ;
Furst, D. E. ;
Mariette, X. ;
van der Heijde, D. ;
van Vollenhoven, R. ;
Arendt, C. ;
Mountian, I. ;
Purcaru, O. ;
Tatla, D. ;
VanLunen, B. ;
Weinblatt, M. E. .
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (01) :96-104
[4]
A RANDOMIZED DOUBLE-BLIND TREATMENT STRATEGY STUDY EVALUATING CONTINUATION OR REDUCED-FREQUENCY DOSING OF CERTOLIZUMAB PEGOL VERSUS WITHDRAWAL TO MAINTAIN LOW DISEASE ACTIVITY IN EARLY RA PATIENTS (C-EARLY PERIOD 2) [J].
Emery, P. ;
Bingham, C. ;
Burmester, G. -R. ;
Bykerk, V. P. ;
Furst, D. ;
Mariette, X. ;
van der Heijde, D. ;
van Vollenhoven, R. ;
VanLunen, B. ;
Ecoffet, C. ;
Cioffi, C. ;
Weinblatt, M. .
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 :143-144
[5]
Felson DT, 2011, ANN RHEUM DIS, V70, P404, DOI [10.1136/ard.2011.149765, 10.1002/art.30129]
[6]
Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study [J].
Haschka, Judith ;
Englbrecht, Matthias ;
Hueber, Axel J. ;
Manger, Bernhard ;
Kleyer, Arnd ;
Reiser, Michaela ;
Finzel, Stephanie ;
Tony, Hans-Peter ;
Kleinert, Stefan ;
Feuchtenberger, Martin ;
Fleck, Martin ;
Manger, Karin ;
Ochs, Wolfgang ;
Schmitt-Haendle, Matthias ;
Wendler, Joerg ;
Schuch, Florian ;
Ronneberger, Monika ;
Lorenz, Hanns-Martin ;
Nuesslein, Hubert ;
Alten, Rieke ;
Demary, Winfried ;
Henes, Joerg ;
Schett, Georg ;
Rech, Juergen .
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (01) :45-51
[7]
Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment [J].
Rech, Juergen ;
Hueber, Axel J. ;
Finzel, Stephanie ;
Englbrecht, Matthias ;
Haschka, Judith ;
Manger, Bernhard ;
Kleyer, Arnd ;
Reiser, Michaela ;
Cobra, Jayme Fogagnolo ;
Figueiredo, Camille ;
Tony, Hans-Peter ;
Kleinert, Stefan ;
Wendler, Joerg ;
Schuch, Florian ;
Ronneberger, Monika ;
Feuchtenberger, Martin ;
Fleck, Martin ;
Manger, Karin ;
Ochs, Wolfgang ;
Schmitt-Haendle, Matthias ;
Lorenz, Hanns-Martin ;
Nuesslein, Hubert ;
Alten, Rieke ;
Henes, Joerg ;
Krueger, Klaus ;
Schett, Georg .
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (09) :1637-1644
[8]
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs [J].
Smolen, Josef S. ;
Landewe, Robert ;
Breedveld, Ferdinand C. ;
Dougados, Maxime ;
Emery, Paul ;
Gaujoux-Viala, Cecile ;
Gorter, Simone ;
Knevel, Rachel ;
Nam, Jackie ;
Schoels, Monika ;
Aletaha, Daniel ;
Buch, Maya ;
Gossec, Laure ;
Huizinga, Tom ;
Bijlsma, Johannes W. J. W. ;
Burmester, Gerd ;
Combe, Bernard ;
Cutolo, Maurizio ;
Gabay, Cem ;
Gomez-Reino, Juan ;
Kouloumas, Marios ;
Kvien, Tore K. ;
Martin-Mola, Emilio ;
McInnes, Iain ;
Pavelka, Karel ;
van Riel, Piet ;
Scholte, Marieke ;
Scott, David L. ;
Sokka, Tuulikki ;
Valesini, Guido ;
van Vollenhoven, Ronald ;
Winthrop, Kevin L. ;
Wong, John ;
Zink, Angela ;
van der Heijde, Desiree .
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (06) :964-975
[9]
Treating rheumatoid arthritis to target: recommendations of an international task force [J].
Smolen, Josef S. ;
Aletaha, Daniel ;
Bijlsma, Johannes W. J. ;
Breedveld, Ferdinand C. ;
Boumpas, Dimitrios ;
Burmester, Gerd ;
Combe, Bernard ;
Cutolo, Maurizio ;
de Wit, Maarten ;
Dougados, Maxime ;
Emery, Paul ;
Gibofsky, Alan ;
Gomez-Reino, Juan Jesus ;
Haraoui, Boulos ;
Kalden, Joachim ;
Keystone, Edward C. ;
Kvien, Tore K. ;
McInnes, Iain ;
Martin-Mola, Emilio ;
Montecucco, Carlomaurizio ;
Schoels, Monika ;
van der Heijde, Desiree .
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (04) :631-637